Introduction (precedes Dr. Aaronson's talk) David Van Wyck, MD
	Managing Anemia in CKD: Experience with High-Dose Iron Infusions Michael Aaronson, MD
	Hot Topics: Current Controversies in Iron Management George Aronoff, MD
	Safety Results of an Iron Sucrose Clinical Trial Chaim Charytan, MD
	Questions and Answers Speakers and moderator

After participating in this activity, participants:

	Will determine that, to assure safety, optimum IV iron therapy in the anemia of chronic kidney disease is guided by theoretical, laboratory and clinical assessment of potential adverse effects
	Will recognize that rate of administration determines, in part, the total iron which can be safely administered in one dose.
	Will consider that the total iron dose which can be administered in a single setting differs among IV iron agents including iron dextran, ferric gluconate, and iron sucrose.
	Will summarize key findings in the US Clinical Trials of Iron Sucrose, and relate those findings to previous literature
	Will consider that high ferritin levels, iron excess and iron deficiency are each associated with poor patient outcomes
	Will realize that maintenance IV iron protocols more effectively prevent iron deficiency and that such protocols should aim to avoid ferritin levels above 800 ng/ml.